Amryt Pharma PLC

$7.84 0.00% ($0.00)

Get ready to invest

About Amryt Pharma PLC

Amryt Pharma plc (Amryt) is a United Kingdom-based commercial-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing treatments to help patients with rare and orphan diseases. Amryt’s commercial business comprises two orphan disease products: metreleptin (Myalept/ Myalepta) and lomitapide (Juxtapid/ Lojuxta). Myalept is approved in the United States as an adjunct to diet as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalised lipodystrophy (GL). Juxtapid is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, homozygous familial hypercholesterolaemia (HoFH). The Company's development candidate, Oleogel-S10 (Filsuvez) is a treatment for the cutaneous manifestations of junctional and dystrophic (JEB and DEB) epidermolysis bullosa. Amryt’s pre-clinical gene therapy platform, AP103, offers treatment for patients with DEB.

Popular Stocks	Price	Change
AMC AMC	$25.1548 1.2%	1.2%
AMD AMD	$100.5604 2.49%	2.49%
SoFi SOFI	$7.51 1.21%	1.21%
Veru Inc VERU	$16.2216 1.32%	1.32%
Invitae NVTA	$4.97 10.2%	10.2%
Pacific Biosciences PACB	$8.795 10.77%	10.77%
Ginkgo Bioworks Holdings DNA	$3.4888 2.61%	2.61%
Snap SNAP	$11.4416 2.98%	2.98%
Ford F	$15.9509 0.76%	0.76%
Apple AAPL	$170.38 1.12%	1.12%